Last reviewed · How we verify
IL-YANG Flu Vaccine Pre-filled Syringe
IL-YANG Flu Vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains included in the vaccine formulation.
IL-YANG Flu Vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains included in the vaccine formulation. Used for Seasonal influenza prevention in adults and/or pediatric populations.
At a glance
| Generic name | IL-YANG Flu Vaccine Pre-filled Syringe |
|---|---|
| Sponsor | Il-Yang Pharm. Co., Ltd. |
| Drug class | inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As an inactivated influenza vaccine in pre-filled syringe format, it contains viral antigens that trigger both humoral (antibody) and cell-mediated immune responses. This prepares the immune system to recognize and neutralize circulating influenza viruses, reducing infection risk and disease severity in vaccinated individuals.
Approved indications
- Seasonal influenza prevention in adults and/or pediatric populations
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Myalgia
- Fatigue
- Headache
Key clinical trials
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children (PHASE3)
- Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: